DNMT1 and myelodysplastic syndrome: The 5-aza-2′-deoxycytidine (decitabine, DAC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor used for the treatment of myelodysplastic syndromes (MDS) and AML [1], and this has been recently considered in the treatment of solid tumors [2].